Recent data confirm a shift in the management of type 2 diabetes, with increasing use of second-line non-insulin therapies (dipeptidyl peptidase-4 [DPP-4] inhibitors, glucagon-like peptide-1 [GLP-1] receptor agonists and sodium−glucose cotransporter 2 [SGLT2] inhibitors) among women of reproductive age [3]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.